If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
The maintenance dose follows the starting dose period of 2 months according to the recommended dose scheme within the range 150 mg to 300 mg every 2 weeks or 300 to 405 mg every 4 weeks.
Information on Maintenance Dose
LAI provides therapeutic levels of systemic olanzapine from the very
first injection. However, approximately 3 months are needed to
re-establish steady state.1
treatment, dose may subsequently be adjusted on the basis of
individual clinical status. After clinical reassessment, dose may be
adjusted within the range 150 mg to 300 mg every 2 weeks or 300 to
405 mg every 4 weeks (Table 1).2
1. Recommended dose scheme between oral olanzapine and olanzapine
oral olanzapine dose
starting dose of olanzapine pamoate
dose after 2 month of olanzapine pamoate treatment
or 405 mg/4 weeks
or 300 mg/4 weeks
or 405 mg/4 weeks
doses of olanzapine LAIhave been shown to sustain
steady-state olanzapine concentrations over 2 to 4 weeks that
correspond to those maintained by an oral dose of 10 to 20 mg
olanzapine administered once daily.3
specific patient populations may require cautious dose escalation.1
For full information please refer to the summary of product
half-life of olanzapine after olanzapine pamoate is 30 days compared
to 30 hours following oral administration.2
the initial three months of treatment with olanzapine pamoate,
accumulation of olanzapine was observed but there was no additional
accumulation during long-term use (12 months) in patients who were
injected with up to 300 mg every two weeks.2
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
ZypAdhera [summary of product characteristics] Eli Lilly Netherland
B.V., The Netherlands.
Mitchell M, Kothare P, Bergstrom R, et al. Single- and multiple-dose
pharmacokinetic, safety, and tolerability profiles of olanzapine
long-acting injection: an open-label, multicenter, nonrandomized
study in patients with schizophrenia. Clin Ther.
= long-acting injection = olanzapine-pamoate
Date of Last Review:May 01, 2019
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com